The NCI Thoracic Malignancy Steering Committee would like to congratulate Lung Cancer Foundation of America’s President, Kim Norris on her election as one of the two Patient Advocate Representatives serving on the committee and welcome her as a new member.
The TMSC functions to harmonize an efficient, cost-effective, science-driven, and transparent process that will identify and promote the “Best Science” in clinical research of lung and other thoracic malignancies by addressing the design and prioritization of phase III trials and large phase II studies in chest malignancies.
You can find out more about NCI Steering Committees on our website: (http://transformingtrials.cancer.gov/steering/overview ) and the TMSC roster is found at: (http://transformingtrials.cancer.gov/steering-committees/thoracic-malignancy ).
Please note, all of the Patient Advocates that participate on the NCI Scientific Steering Committees are also invited to participate on the NCI Patient Advocate Steering Committee (PASC). The PASC functions to develop and share best practices to support the role of patient advocates across all the Steering Committees.